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Nutritional supplements sometimes contain 
adulterated and undeclared substances. 
Gabriels et al. reported several incidences 
where nutritional supplements tested 
positive for harmful and undeclared 
substances not indicated on the labels.[1,2] Of 138 nutritional 
supplements commercially available in South Africa, 47% 
tested positive for melamine[1] and 54% for fluoxetine.[2] 
Whilst the median melamine concentration was below the 
Tolerable Daily Intake (TDI) and the level of fluoxetine 
contamination low, these substances were not indicated on 
the labels.[1] Melamine is used in plastics and fertilisers, and 
artificially boosts the protein level in food.[3] Fluoxetine, a 
selective serotonin reuptake inhibitor, is used to treat major 
depression and bulimia nervosa.[4] 
A Canadian manufacturer of sports supplements 
promotes a muscle- and testosterone-boosting product in 
South Africa via retailers and sports and nutritional outlets. 
The manufacturer’s advertisements use science sounding 
efficacy claims for this product, supported by images of 
hypermasculine men. Men suffering from muscle 
dysmorphia are ideally the intended target audience. This 
pathological disorder seems to make them more 
susceptible to appeals for a more muscular physique, and 
even a brief exposure to the aforementioned imagery, may 
induce the desired effect.[5] Men with muscle dysmorphia 
are also more likely to experiment with anabolic steroids 
and other performance-enhancing substances.[6] 
The objective of this paper is to illustrate how labelling 
claims of one such product, a purported testosterone 
booster, potentially mislead consumers by misusing and 
exaggerating scientific information. This product, as an 
illustrative example, is but one of many similar products 
that misuses the same scientific information that appeared 
in a reproductive and endocrinology journal.[7] The 
following sections report on the process, claims and 
evidence supplied by the advertiser, and conclude by 
questioning these advertising claims.  
Case report 
The process 
An email was sent to the company requesting information on 
the advertising claims. The information provided did not 
support their advertising claims. A visit to a store that sold the 
product, followed by a subsequent email, inquired whether 
the store holds sufficient evidence for supporting the 
advertising claims.  The store manager received information 
from the company and via email, presented three scientific 
articles [7, 8, 9] and an Evidence and Safety Summary Report as 
purported evidence for the product’s efficacy claims. The 
advertiser’s claims were compared against the evidence 
supplied by the advertiser, and empirical results pertaining to 
the effect of exogenous D-aspartic acid, the product’s key 
ingredient, on human testosterone.  
The term ‘D-aspartic acid’ (and its derivatives) combined 
with ‘testosterone’ were used as keywords to search for in vivo 
studies on exogenous D-aspartic acid and its effect on human 
testosterone levels. However, the search did not reveal any 
relevant articles in the Cochrane Database of Systematic 
Reviews or reputable urology journals to support a notion that 
exogenous D-aspartic acid will increase testosterone levels in 
humans. The Aspartates monograph, available from the 
Natural Medicines Comprehensive Database, does not list D-
aspartic acid as a testosterone booster, only stating that people 
use it for the absorption of supplements and athletic 
performance. The monograph further cautions that sufficient 
and reliable information about its safety and effectiveness is 
not available.[10]  
 
The product’s labelling claims 
The labelling claims for the product is about its efficacy, which 
is shown on a website and the product’s packaging. These 
claims are that the product can increase, support, stimulate, 
amplify, and boost testosterone levels. Additional claims are 
that the product has been clinically researched and that its 
results are clinically proven. 
 
The advertiser’s evidence 
The first article is a study that deals with rats and not human 
participants and was therefore dismissed.[8] The second article 
is a summary of current and previous work on the role of D-
aspartic acid in the nervous and endocrine systems of 
invertebrates and vertebrates, including mammals.[9] 
However, it does not cover any studies on the advertised 
testosterone boosting product or any similar products, nor 
This paper illustrates how labelling claims of a testosterone booster supplement mislead consumers. The labelling claims 
misappropriate scientific terminology, exaggerate and misrepresent research as evidence for the product’s purported efficacy. 
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does it look at the increase of testosterone in humans. The 
third article is a study by Topo et al.[7] and could be considered 
as the only bona fide attempt at providing evidence for this 
product’s efficacy claims. It reports on the role and molecular 
mechanism of D-aspartic acid in the release and synthesis of 
luteinising hormone (LH), and testosterone in humans and in 
rats. The fourth document is the manufacturer’s own Evidence 
and Safety Summary Report which provides summaries of the 
three previously mentioned studies and lists an additional 
eight articles. One of these articles is about the nomenclature 
and symbolism of amino acids and peptides. The other seven 
articles are about the claimed safety and health benefits of 
resveratrol, rhodiola, and vitamins. These eight additional 
articles do not provide any information to support the 
product’s testosterone boosting claims. 
 
Are the claims misleading? 
The claim regarding D-aspartic acid as a testosterone boosting 
agent is misleading for several reasons. The advertiser misuses 
and misrepresents scientific information from the Topo et al.[7] 
study and contradicts the results of other scientific studies. 
The advertiser’s claims are interrogated below. 
The first argument is that the advertiser misuses scientific 
information, particularly tabulated data from the Topo et al.[7] 
study, which are reproduced below. 
The total testosterone in the Topo et al.[7] study increased 
from a mean of 4.5 (± 0.6) ng/ml serum at zero time to 6.4 (± 
0.8) ng/ml after 12 days of use. This then decreased to 5.8 (± 
0.6) ng/ml after three days of suspension of D-aspartic acid 
treatment (for the treatment group). The increase from 4.5 to 
6.4 translates to an increase of 42%, a value given on the 
product’s website to validate their claim of increased 
testosterone levels. The increase from 4.5 ng/ml to 6.4 ng/ml 
may be statistically significant but will nonetheless not have 
any noticeable effect on a user. As such, the results may be 
statistically significant but clinically insignificant. Clinical 
significance or the practical value of an increase would be 
when free testosterone levels increase beyond the upper 
threshold for the consumer’s age group. The Topo et al.[7] 
study also did not calculate and report on free testosterone, 
only on total testosterone. Total testosterone consists of 
testosterone bound to sex hormone binding globulin (SHBG) 
and free testosterone. Free testosterone is a portion of 
circulating testosterone that crosses cell membranes, exerts a 
biologic effect and contributes, inter alia, to muscle strength. 
Although there was a statistically significant increase in total 
testosterone, the increase is still in the lower range of 
testosterone levels in healthy adult males. It is thus highly 
unlikely that this small increase, even for men with low levels 
of testosterone, would produce a discernible effect on their 
ability to build muscle. What is noteworthy from the Topo et 
al.[7] study is that the volunteers (treatment = 23; placebo = 20) 
were tested at an in vitro fertilisation clinic. The mean base 
levels of total testosterone for the treatment and placebo 
groups were low, namely 4.6 (±0.5) ng/ml and 4.5 (±0.6) ng/ml. 
Although the Topo et al.[7] paper states that the test 
participants were healthy, these base levels are at the lower 
range of total testosterone for males.  The participants did not 
come from a population of men with total testosterone levels 
that are spread over the normal range. The normal range of 
total testosterone levels for men (19-39 years) range from 2.67 
ng/ml to 9.29 ng/ml.[11] 
The second reason for arguing that the claims are misleading 
is the difference in the time usage of the different products. 
The participants in the Topo et al.[7] study received a solution 
with D-aspartic acid for 12 days. The advertiser’s product 
contained 96 capsules which, according to the package design, 
equates to a 30 day cycle. As such, the results are not directly 
transferable. 
The third reason for misleading the consumer is that the 
Topo et al.[7] study used a different product and not the 
advertiser’s product for testing. The ingredients and the D-
aspartic acid dosage (3120 mg/day) are similar, except that the 
advertiser added resveratrol and rhodiola.  
The fourth reason why the claims could be considered as 
misleading is that they contradict recent studies. A systematic 
review by Roshanzamir and Safavi [12] identified 27 relevant 
studies, of which only four were in vivo human studies. They 
concluded that ‘more and high-quality randomized controlled 
trials need to be conducted on D-Asp supplementation 
regarding their ability to increase endogenous levels of 
testosterone and elucidating the mechanisms of its action in 
human research’. 
The fifth reason for misleading the consumer is how the 
advertiser used bar graphs on their website to illustrate the 
results of the Topo et al.[7] study. The bar graphs only show the 
upper half of the results and exaggerate the difference 
between the experimental and placebo groups. The advertiser 
starts the baseline at 3.5 for LH and 4 for testosterone instead 
of 0 (i.e. at the bottom of the graph). Only showing the upper 
parts of a bar graph accentuates an otherwise small difference. 
The advertiser did not mention the decline in the participant’s 
total testosterone three days after the suspension of D-aspartic 
acid (the data in the far right column, Table 1), and did not 
indicate this decline in the bar graph.  
Table 1. Effects of D-aspartate (D-Asp) on luteinising hormone (LH) and testosterone release in human serum (Topo et al.)[7] 
 
Basal levels 
treatment 
After six days of  
D-Asp treatment 
After 12 days  
of D-Asp 
Three days after the 
suspension of D-Asp 
LH (mIU/ml serum)     
Subjects treated with Na-D-aspartate 4.2 ± 0.5 4.5 ± 0.6  5.6 ± 0.9* 4.8 ± 0.8 
Subjects treated with placebo 4.2 ± 0.4 4.3 ± 0.7 4.2 ± 0.6 4.1 ± 0.5 
Testosterone (ng/ml serum)     
Subjects treated with Na-D-aspartate 4.5 ± 0.6 5.2 ± 0.7  6.4 ± 0.8*  5.8 ± 0.6* 
Subjects treated with placebo 4.6 ± 0.5 4.5 ± 0.7 4.7 ± 0.7 4.6 ± 0.7 
* Values are statistically significant for p < 0.001[7] 
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Conclusion 
When confronted with claims such as ‘100% clinically 
validated’ and ‘clinically researched’ the consumer could infer 
that the product has been subjected to relevant, unbiased and 
independent clinical trials, that it is safe and effective, and that 
there is sufficient scientific evidence to support these claims. 
From the manufacturer’s supplied information, it is clear that 
no such trials ever took place. The textual claims and the 
partial histogram misrepresent and exaggerate the scientific 
results, potentially misleading consumers. There are limited in 
vivo human studies on the effect of exogenous D-aspartic acid 
on testosterone blood serum.[12] The evidence of the small and 
short duration studies is insufficient to conclude that D-
aspartic acid leads to a substantial and clinically significant 
increase in testosterone levels. Problems related to the 
supplement industry are not only limited to regulatory 
matters, adulteration, contamination and unsubstantiated 
claims, but also include deception and potentially misleading 
advertising. 
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